{"meta":{"totalResults":36,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"177Lu-AB-3PRGD2"},{"type":"Synonym","name":"177Lu-3PRGD2"}],"definition":{"html":"A radiopharmaceutical agent comprised of a pegylated cyclic arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with lutetium Lu 177, with potential antineoplastic activity against alphaVbeta3 integrin-expressing tumor cells. Upon administration of lutetium Lu 177 AB-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on alphaVbeta3 integrin-expressing tumor cells. The tumor cells can be eradicated upon direct cytotoxicity through beta radiation. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.","text":"A radiopharmaceutical agent comprised of a pegylated cyclic arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with lutetium Lu 177, with potential antineoplastic activity against alphaVbeta3 integrin-expressing tumor cells. Upon administration of lutetium Lu 177 AB-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on alphaVbeta3 integrin-expressing tumor cells. The tumor cells can be eradicated upon direct cytotoxicity through beta radiation. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival."},"drugInfoSummaryLink":null,"nciConceptId":"C184308","nciConceptName":"Lutetium Lu 177 AB-3PRGD2","termId":806321,"name":"lutetium Lu 177 AB-3PRGD2","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-ab-3prgd2"},{"aliases":[{"type":"Synonym","name":"177Lu-CHX-A''-DTPA-HuMab-5B1"},{"type":"Synonym","name":"177Lu human monoclonal antibody 5B1"},{"type":"Synonym","name":"Lu 177 anti-CA19-9 monoclonal antibody 5B1"},{"type":"CodeName","name":"MVT-1075"}],"definition":{"html":"A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A''-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.","text":"A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A''-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis."},"drugInfoSummaryLink":null,"nciConceptId":"C142176","nciConceptName":"Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1","termId":791457,"name":"lutetium Lu 177 anti-CA19-9 monoclonal antibody 5B1","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-anti-ca19-9-monoclonal-antibody-5b1"},{"aliases":[{"type":"Synonym","name":"177Lu-anti-PD-L1 single domain antibody RAD204"},{"type":"Synonym","name":"177Lu-RAD-204"},{"type":"Synonym","name":"177Lu-RAD204"},{"type":"Synonym","name":"[Lu-177]RAD204"},{"type":"Synonym","name":"lutetium Lu 177 anti-PD-L1 nanobody RAD-204"},{"type":"Synonym","name":"lutetium Lu 177-labeled anti-PD-L1 nanobody RAD204"}],"definition":{"html":"A radioimmunoconjugate composed of a nanobody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and labeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging activity of PD-L1 tumor antigen expression during single-photon emission computerized tomography/computerized tomography (SPECT/CT) and with potential antineoplastic activity. Upon administration of lutetium Lu 177 anti-PD-L1 nanobody RAD204, the RAD204 moiety targets and binds to the PD-L1 expressed on certain tumor cells. Upon uptake and imaging, the radioisotope moiety can be visualized and the extent of PD-L1 expression can be assessed. Also, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PD-L1-expressing tumor cells. PD-L1, a transmembrane protein, is overexpressed on the surface of many cancer cell types.","text":"A radioimmunoconjugate composed of a nanobody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and labeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging activity of PD-L1 tumor antigen expression during single-photon emission computerized tomography/computerized tomography (SPECT/CT) and with potential antineoplastic activity. Upon administration of lutetium Lu 177 anti-PD-L1 nanobody RAD204, the RAD204 moiety targets and binds to the PD-L1 expressed on certain tumor cells. Upon uptake and imaging, the radioisotope moiety can be visualized and the extent of PD-L1 expression can be assessed. Also, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PD-L1-expressing tumor cells. PD-L1, a transmembrane protein, is overexpressed on the surface of many cancer cell types."},"drugInfoSummaryLink":null,"nciConceptId":"C211548","nciConceptName":"Lutetium Lu 177 Anti-PD-L1 Nanobody RAD204","termId":816852,"name":"lutetium Lu 177 anti-PD-L1 nanobody RAD204","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-anti-pd-l1-nanobody-rad204"},{"aliases":[{"type":"Synonym","name":"[177Lu]DOTA-biotin"},{"type":"Synonym","name":"177Lu-ST2210"}],"definition":{"html":"A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication.","text":"A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication."},"drugInfoSummaryLink":null,"nciConceptId":"C113801","nciConceptName":"Lutetium Lu 177 DOTA-biotin","termId":757658,"name":"lutetium Lu 177 DOTA-biotin","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota-biotin"},{"aliases":[{"type":"Synonym","name":"lutetium Lu 177 DOTA-azide-CTT1403"},{"type":"Synonym","name":"177Lu-DOTA-N3-CTT1403"},{"type":"Synonym","name":"177Lu-DOTA-azide-CTT1403"}],"definition":{"html":"A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate.","text":"A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate."},"drugInfoSummaryLink":null,"nciConceptId":"C158044","nciConceptName":"Lutetium Lu 177 DOTA-N3-CTT1403","termId":797172,"name":"lutetium Lu 177 DOTA-N3-CTT1403","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota-n3-ctt1403"},{"aliases":[{"type":"Synonym","name":"177Lu-Dota-tetulomab"},{"type":"ForeignBrandName","name":"Betalutin"},{"type":"Synonym","name":"177Lu-HH1"},{"type":"Synonym","name":"177Lu-DOTA-HH1"}],"definition":{"html":"A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.","text":"A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies."},"drugInfoSummaryLink":null,"nciConceptId":"C105403","nciConceptName":"Lutetium Lu 177 DOTA-Tetulomab","termId":746917,"name":"lutetium Lu 177 DOTA-tetulomab","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota-tetulomab"},{"aliases":[{"type":"Synonym","name":"lutetium Lu 177-DOTATATE"},{"type":"Abbreviation","name":"177 Lu-DOTA-TATE"},{"type":"Synonym","name":"177 Lu-DOTA-Tyr3-octreotate"},{"type":"Synonym","name":"lutetium oxodotreotide LU-177"},{"type":"USBrandName","name":"Lutathera"},{"type":"Synonym","name":"177Lu-DOTA0-Tyr3-Octreotate"},{"type":"CASRegistryName","name":"437608-50-9"},{"type":"Synonym","name":"lutetium Lu 177 DOTA(0)-Tyr(3)-octreotate"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-Tyr3-octreotate"}],"definition":{"html":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","text":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/lutetiumLu177-dotatate","text":"Lutetium Lu 177-Dotatate"},"nciConceptId":"C95020","nciConceptName":"Lutetium Lu 177 Dotatate","termId":715523,"name":"lutetium Lu 177 dotatate","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dotatate"},{"aliases":[{"type":"Synonym","name":"[177Lu]Lu-DPI-4452"},{"type":"Synonym","name":"CA IX-targeted radioconjugate Debio 0228"},{"type":"CodeName","name":"Debio 0228"},{"type":"CodeName","name":"Debio-0228"},{"type":"CodeName","name":"Debio0228"},{"type":"CodeName","name":"ITM 91"},{"type":"CodeName","name":"ITM-91"},{"type":"CodeName","name":"ITM91"},{"type":"Synonym","name":"lutetium Lu 177 DPI-4452"}],"definition":{"html":"A radioconjugate composed of the DOTA cyclic peptide DPI-4452, a carbonic anhydrase IX (CAIX; CA9)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against CAIX-expressing tumor cells. Upon intravenous administration, lutetium Lu 177 DPI-4452 Debio 0228 targets and binds to CAIX-expressing tumor cells. Upon binding, CAIX-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. CAIX is a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. Induced by hypoxia, CAIX is overexpressed in various hypoxic tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, tumor aggressiveness ad resistance to treatment.","text":"A radioconjugate composed of the DOTA cyclic peptide DPI-4452, a carbonic anhydrase IX (CAIX; CA9)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against CAIX-expressing tumor cells. Upon intravenous administration, lutetium Lu 177 DPI-4452 Debio 0228 targets and binds to CAIX-expressing tumor cells. Upon binding, CAIX-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. CAIX is a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. Induced by hypoxia, CAIX is overexpressed in various hypoxic tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, tumor aggressiveness ad resistance to treatment."},"drugInfoSummaryLink":null,"nciConceptId":"C216089","nciConceptName":"Lutetium Lu 177 DPI-4452 Debio 0228","termId":817873,"name":"lutetium Lu 177 DPI-4452 Debio 0228","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dpi-4452-debio-0228"},{"aliases":[{"type":"Synonym","name":"177Lu-EB-PSMA-617"},{"type":"Synonym","name":"177 Lu-EB-PSMA-617"},{"type":"Synonym","name":"177Lu-Evans Blue-modified PSMA-617"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-EB-PSMA-617"},{"type":"Synonym","name":"lutetium Lu 177-EB-PSMA-617"}],"definition":{"html":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the Evans blue (EB) moiety and linked via the macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 EB-PSMA-617, EB-PSMA-617 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors. EB-PSMA-617 also binds to serum albumin, which extends its circulation half-life. This may improve tumor uptake and efficacy of the agent. \n","text":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the Evans blue (EB) moiety and linked via the macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 EB-PSMA-617, EB-PSMA-617 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors. EB-PSMA-617 also binds to serum albumin, which extends its circulation half-life. This may improve tumor uptake and efficacy of the agent. \n"},"drugInfoSummaryLink":null,"nciConceptId":"C179672","nciConceptName":"Lutetium Lu 177 EB-PSMA-617","termId":804999,"name":"lutetium Lu 177 EB-PSMA-617","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-eb-psma-617"},{"aliases":[{"type":"Synonym","name":"177Lu-FF58"},{"type":"Synonym","name":"[177Lu]-FF58"}],"definition":{"html":"A radioconjugate composed of FF58, a non-arginine-glycine-aspartic acid (Arg-Gly-Asp/RGD) small molecule targeting the transmembrane receptors integrin alpha V beta 3 (avb3) and 5 (avb5), linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against integrin avb3/5-expressing tumor cells. Upon administration, lutetium Lu 177 FF58 targets and binds to integrin avb3/5-expressing tumor cells. Upon binding, integrin avb3/5-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. Integrin avb3/5, members of the integrin receptor family, are overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; they play key roles in angiogenesis, tumor proliferation and survival.","text":"A radioconjugate composed of FF58, a non-arginine-glycine-aspartic acid (Arg-Gly-Asp/RGD) small molecule targeting the transmembrane receptors integrin alpha V beta 3 (avb3) and 5 (avb5), linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against integrin avb3/5-expressing tumor cells. Upon administration, lutetium Lu 177 FF58 targets and binds to integrin avb3/5-expressing tumor cells. Upon binding, integrin avb3/5-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. Integrin avb3/5, members of the integrin receptor family, are overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; they play key roles in angiogenesis, tumor proliferation and survival."},"drugInfoSummaryLink":null,"nciConceptId":"C205213","nciConceptName":"Lutetium Lu 177 FF58","termId":815493,"name":"lutetium Lu 177 FF58","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-ff58"},{"aliases":[{"type":"Synonym","name":"177Lu-LNC1004"},{"type":"Synonym","name":"lutetium Lu 177-LNC1004"}],"definition":{"html":"A radioconjugate consisting of an Evans blue (EB) modified fibroblast activation protein inhibitor (FAPi), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177 LNC1004, the FAPi moiety targets and binds to FAP-expressing cancer-associated fibroblasts (CAFs). Upon binding and internalization, the radioconjugate specifically delivers a cytotoxic dose of beta radiation to FAP-expressing CAFs. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME).","text":"A radioconjugate consisting of an Evans blue (EB) modified fibroblast activation protein inhibitor (FAPi), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177 LNC1004, the FAPi moiety targets and binds to FAP-expressing cancer-associated fibroblasts (CAFs). Upon binding and internalization, the radioconjugate specifically delivers a cytotoxic dose of beta radiation to FAP-expressing CAFs. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME)."},"drugInfoSummaryLink":null,"nciConceptId":"C200128","nciConceptName":"Lutetium Lu 177 LNC1004","termId":812593,"name":"lutetium Lu 177 LNC1004","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-lnc1004"},{"aliases":[{"type":"Synonym","name":"[177Lu] ludotadipep"},{"type":"Synonym","name":"Lu 177 ludotadipep"}],"definition":{"html":"A radioconjugate composed of ludotadipep, a prostate-specific membrane antigen (PSMA)-targeting agent, linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon administration, lutetium Lu 177 ludotadipep targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.\n","text":"A radioconjugate composed of ludotadipep, a prostate-specific membrane antigen (PSMA)-targeting agent, linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon administration, lutetium Lu 177 ludotadipep targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C192813","nciConceptName":"Lutetium Lu 177 Ludotadipep","termId":804168,"name":"lutetium Lu 177 ludotadipep","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-ludotadipep"},{"aliases":[{"type":"Synonym","name":"177 Lu-CC49"}],"definition":{"html":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers.","text":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, and so may be used in radioimmunotherapeutic treatment of cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C2598","nciConceptName":"Lutetium Lu 177 Monoclonal Antibody CC49","termId":38083,"name":"lutetium Lu 177 monoclonal antibody CC49","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-monoclonal-antibody-cc49"},{"aliases":[{"type":"Synonym","name":"177Lu-labeled NYM032"},{"type":"Synonym","name":"177Lu-NY108"},{"type":"Synonym","name":"177Lu-NYM032"},{"type":"Synonym","name":"lutetium Lu 177 NY 108"}],"definition":{"html":"A radioconjugate composed of NYM032, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration, lutetium Lu 177 NYM032 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by direct cytotoxicity through beta radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.","text":"A radioconjugate composed of NYM032, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration, lutetium Lu 177 NYM032 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by direct cytotoxicity through beta radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors."},"drugInfoSummaryLink":null,"nciConceptId":"C216090","nciConceptName":"Lutetium Lu 177 NYM032","termId":817761,"name":"lutetium Lu 177 NYM032","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-nym032"},{"aliases":[{"type":"Synonym","name":"177Lu-PP-F11N"}],"definition":{"html":"A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types.","text":"A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types."},"drugInfoSummaryLink":null,"nciConceptId":"C114499","nciConceptName":"Lutetium Lu 177 PP-F11N","termId":759373,"name":"lutetium Lu 177 PP-F11N","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-pp-f11n"},{"aliases":[{"type":"Synonym","name":"(177Lu) rhPSMA-10.1"},{"type":"Synonym","name":"177Lu rhPSMA-10.1"},{"type":"Synonym","name":"177Lu radiohybrid PSMA-10.1"},{"type":"Synonym","name":"177Lu-rhPSMA-10.1"}],"definition":{"html":"A radioconjugate composed of PSMA-10.1, a prostate-specific membrane antigen (PSMA)-targeting ligand and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 PSMA-10.1, PSMA-10.1 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.","text":"A radioconjugate composed of PSMA-10.1, a prostate-specific membrane antigen (PSMA)-targeting ligand and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 PSMA-10.1, PSMA-10.1 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors."},"drugInfoSummaryLink":null,"nciConceptId":"C188236","nciConceptName":"Lutetium Lu 177 Tezuvotide Tetraxetan","termId":810055,"name":"lutetium Lu 177 PSMA-10.1","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-tezuvotide-tetraxetan"},{"aliases":[{"type":"Synonym","name":"177Lu-PSMA-EB-01"},{"type":"Synonym","name":"lutetium Lu 177-labeled PSMA-EB-01"},{"type":"Synonym","name":"lutetium Lu 177-LNC1003"},{"type":"Synonym","name":"[177Lu]Lu-LNC1003"}],"definition":{"html":"A radioconjugate composed of PSMA-EB-01, a human prostate-specific membrane antigen (PSMA)-targeting ligand conjugated to the Evans blue (EB) moiety, and linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 PSMA-EB-01, PSMA-EB-01 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors. The EB moiety of PSMA-EB-01 binds to serum albumin, which extends its circulation half-life. This may improve tumor uptake and efficacy of the agent.\n","text":"A radioconjugate composed of PSMA-EB-01, a human prostate-specific membrane antigen (PSMA)-targeting ligand conjugated to the Evans blue (EB) moiety, and linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 PSMA-EB-01, PSMA-EB-01 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors. The EB moiety of PSMA-EB-01 binds to serum albumin, which extends its circulation half-life. This may improve tumor uptake and efficacy of the agent.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C193469","nciConceptName":"Lutetium Lu 177 PSMA-EB-01","termId":811809,"name":"lutetium Lu 177 PSMA-EB-01","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-psma-eb-01"},{"aliases":[{"type":"Synonym","name":"177Lu-DOTA-TLX591"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-TLX591"},{"type":"LexicalVariant","name":"Lutetium Lu 177 Rosopatamab Tetraxetan"},{"type":"Synonym","name":"DOTA-HUJ-591 LU-177"},{"type":"Synonym","name":"lutetium Lu 177 rosopatamab"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-rosopatamab"}],"definition":{"html":"A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.\n","text":"A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C38701","nciConceptName":"Lutetium Lu 177 Rosopatamab Tetraxetan","termId":361550,"name":"lutetium Lu 177 rsopatamab tetraxetan","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-rosopatamab-tetraxetan"},{"aliases":[{"type":"Synonym","name":"177Lu-DOTA-JR11"},{"type":"Synonym","name":"177Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]"},{"type":"Synonym","name":"177Lu-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2"},{"type":"ForeignBrandName","name":"SOMther"},{"type":"Synonym","name":"Lu-177 OPS-201"},{"type":"Synonym","name":"satoreotide tetraxetan lutetium-177"},{"type":"Synonym","name":"177Lu-satoreotide tetraxetan"},{"type":"CASRegistryName","name":"1934243-21-6"}],"definition":{"html":"A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.","text":"A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs."},"drugInfoSummaryLink":null,"nciConceptId":"C124929","nciConceptName":"Lutetium Lu 177 Satoreotide Tetraxetan","termId":777267,"name":"lutetium Lu 177 satoreotide tetraxetan","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-satoreotide-tetraxetan"},{"aliases":[{"type":"Synonym","name":"lutetium-177-PSMA-617"},{"type":"Synonym","name":"lutetium Lu 177-PSMA-617"},{"type":"Synonym","name":"177Lu-PSMA-617"},{"type":"USBrandName","name":"Pluvicto"},{"type":"Synonym","name":"177Lu-labeled PSMA-617"},{"type":"Synonym","name":"Lu177-PSMA-617"},{"type":"CodeName","name":"AAA-617"},{"type":"CodeName","name":"AAA617"},{"type":"CodeName","name":"AAA 617"},{"type":"CASRegistryName","name":"1703749-62-5"}],"definition":{"html":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.","text":"A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/lutetium-Lu-177-vipivotide-tetraxetan","text":"Lutetium Lu 177 Vipivotide Tetraxetan"},"nciConceptId":"C148145","nciConceptName":"Lutetium Lu 177 Vipivotide Tetraxetan","termId":792497,"name":"lutetium Lu 177 vipivotide tetraxetan","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-vipivotide-tetraxetan"},{"aliases":[{"type":"Synonym","name":"177Lu-labeled XT117"},{"type":"Synonym","name":"[177Lu]Lu-XT117"},{"type":"Synonym","name":"Lu-177-XT117"}],"definition":{"html":"A radioconjugate composed of XT117, a fibroblast activation protein inhibitor (FAPi), conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against FAP-expressing cancer-associated fibroblasts (CAFs). Upon administration, lutetium Lu 177 XT117 targets and binds to FAP-expressing CAFs. Upon binding, FAP-expressing CAFs are destroyed by 177Lu through the specific delivery of beta particle radiation. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME) of various cancers.","text":"A radioconjugate composed of XT117, a fibroblast activation protein inhibitor (FAPi), conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against FAP-expressing cancer-associated fibroblasts (CAFs). Upon administration, lutetium Lu 177 XT117 targets and binds to FAP-expressing CAFs. Upon binding, FAP-expressing CAFs are destroyed by 177Lu through the specific delivery of beta particle radiation. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME) of various cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C206262","nciConceptName":"Lutetium Lu 177 XT117","termId":815528,"name":"lutetium Lu 177 XT117","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-xt117"},{"aliases":[{"type":"Synonym","name":"177Lu-meO-DOTA-7E11"},{"type":"CodeName","name":"CYT-500"}],"definition":{"html":"A radioimmunoconjugate consisting of capromab linked to lutetium Lu 177 via the bifunctional macrocyclic chelator methoxy-tetraazacyclododecane-tetraacetic acid (MeO-DOTA)  with potential antineoplastic activity. Lutetium Lu 177-capromab binds to human prostate specific membrane antigen (PSMA) expressed on tumor cell surfaces via its capromab moiety and, upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells.  PSMA is  a cell surface glycoprotein abundantly expressed by prostate epithelium and is typically overexpressed by prostate cancer cells.","text":"A radioimmunoconjugate consisting of capromab linked to lutetium Lu 177 via the bifunctional macrocyclic chelator methoxy-tetraazacyclododecane-tetraacetic acid (MeO-DOTA)  with potential antineoplastic activity. Lutetium Lu 177-capromab binds to human prostate specific membrane antigen (PSMA) expressed on tumor cell surfaces via its capromab moiety and, upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells.  PSMA is  a cell surface glycoprotein abundantly expressed by prostate epithelium and is typically overexpressed by prostate cancer cells."},"drugInfoSummaryLink":null,"nciConceptId":"C67039","nciConceptName":"Lutetium Lu-177 Capromab","termId":539702,"name":"lutetium Lu 177-capromab","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-capromab"},{"aliases":[{"type":"Synonym","name":"177Lu-DOTA"},{"type":"Synonym","name":"177Lu-labeled DOTA"},{"type":"Synonym","name":"Lu-177-DOTA"}],"definition":{"html":"A radioconjugate composed of the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177), that can be used for radioimmunotherapeutic purposes. Upon administration, Lu-177-DOTA may act as a hapten for pretargeted radioimmunotherapy, and delivers targeted beta radiation.","text":"A radioconjugate composed of the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177), that can be used for radioimmunotherapeutic purposes. Upon administration, Lu-177-DOTA may act as a hapten for pretargeted radioimmunotherapy, and delivers targeted beta radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C190827","nciConceptName":"Lutetium Lu 177-DOTA","termId":811237,"name":"lutetium Lu 177-DOTA","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota"},{"aliases":[{"type":"Synonym","name":"[177Lu]-DOTA-ABM-5G"}],"definition":{"html":"A radioconjugate composed of 5G, an agent targeting an as of yet undisclosed target, conjugated, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and an albumin binding moiety (ABM), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177-DOTA-ABM-5G, the 5G moiety targets and binds to a specific target on tumor cells. Upon binding, lutetium Lu 177 delivers a cytotoxic dose of beta radiation to the tumor cells.","text":"A radioconjugate composed of 5G, an agent targeting an as of yet undisclosed target, conjugated, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and an albumin binding moiety (ABM), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177-DOTA-ABM-5G, the 5G moiety targets and binds to a specific target on tumor cells. Upon binding, lutetium Lu 177 delivers a cytotoxic dose of beta radiation to the tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C176853","nciConceptName":"Lutetium Lu 177-DOTA-ABM-5G","termId":803809,"name":"lutetium Lu 177-DOTA-ABM-5G","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota-abm-5g"},{"aliases":[{"type":"Synonym","name":"Lu-177-labeled di-histamine-succinyl-glycine-DOTA peptide IMP-288"}],"definition":{"html":"A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the radionuclide lutetium (Lu) 177. After pretargeting with a bispecific monoclonal antibody (BiMoAB) directed against both a tumor associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of administered Lu-177-labeled di-HSG-DOTA peptide IMP-288 binds the anti-HSG portion of the BiMoAB;  Lu-177 radioisotopic activity localized to tumor cells bearing the TAA can then be visualized scintigraphically.","text":"A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the radionuclide lutetium (Lu) 177. After pretargeting with a bispecific monoclonal antibody (BiMoAB) directed against both a tumor associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of administered Lu-177-labeled di-HSG-DOTA peptide IMP-288 binds the anti-HSG portion of the BiMoAB;  Lu-177 radioisotopic activity localized to tumor cells bearing the TAA can then be visualized scintigraphically."},"drugInfoSummaryLink":null,"nciConceptId":"C82354","nciConceptName":"Lutetium Lu 177-DOTA-di-HSG Peptide IMP-288","termId":639752,"name":"lutetium Lu 177-DOTA-di-HSG peptide IMP-288","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota-di-hsg-peptide-imp-288"},{"aliases":[{"type":"Synonym","name":"177Lu-DOTA-EB-TATE"},{"type":"Synonym","name":"lutetium-177-DOTA-EB-TATE"},{"type":"Synonym","name":"lutetium Lu 177 DOTA(0)-EB-Tyr(3)-octreotate"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-EB-Tyr3-octreotate"},{"type":"Synonym","name":"177 Lu-DOTA-EB-TATE"},{"type":"Synonym","name":"177Lu-DOTA0-EB-Tyr3-octreotate"},{"type":"Synonym","name":"lutetium-177-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate"}],"definition":{"html":"A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Upon intravenous administration, Lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows Lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.","text":"A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Upon intravenous administration, Lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows Lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues."},"drugInfoSummaryLink":null,"nciConceptId":"C154549","nciConceptName":"Lutetium Lu 177-DOTA-EB-TATE","termId":794348,"name":"lutetium Lu 177-DOTA-EB-TATE","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dota-eb-tate"},{"aliases":[{"type":"Synonym","name":"177Lu-3BP-227"},{"type":"Synonym","name":"177Lu-IPN01087"},{"type":"Synonym","name":"177Lu-DOTA-3BP-227"},{"type":"Synonym","name":"177Lu-DOTA-IPN01087"},{"type":"Synonym","name":"lutetium Lu 177 DOTA-3BP-227"}],"definition":{"html":"A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-IPN01087 binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue.","text":"A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-IPN01087 binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue."},"drugInfoSummaryLink":null,"nciConceptId":"C157630","nciConceptName":"Lutetium Lu 177 Zalsenertant Tetraxetan","termId":796889,"name":"lutetium Lu 177-DOTA-IPN01087","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-zalsenertant-tetraxetan"},{"aliases":[{"type":"Synonym","name":"177Lu-DTPA-omburtamab"}],"definition":{"html":"A radioimmunoconjugate consisting of omburtamab, a murine immunoglobulin G1 (IgG1) antibody directed against the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276), conjugated, via the chelating agent diethylenetriaminepentaacetic acid (DTPA), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intracerebroventricular administration of lutetium Lu 177-DTPA-omburtamab, the omburtamab moiety binds to B7-H3 expressed on certain tumor cells. Upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis.","text":"A radioimmunoconjugate consisting of omburtamab, a murine immunoglobulin G1 (IgG1) antibody directed against the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276), conjugated, via the chelating agent diethylenetriaminepentaacetic acid (DTPA), to the radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intracerebroventricular administration of lutetium Lu 177-DTPA-omburtamab, the omburtamab moiety binds to B7-H3 expressed on certain tumor cells. Upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis."},"drugInfoSummaryLink":null,"nciConceptId":"C174423","nciConceptName":"Lutetium Lu 177-DTPA-omburtamab","termId":802279,"name":"lutetium Lu 177-DTPA-omburtamab","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-dtpa-omburtamab"},{"aliases":[{"type":"Synonym","name":"177Lu-EB-LM3"},{"type":"Synonym","name":"177Lu-Evans blue-modified LM3"}],"definition":{"html":"A radioconjugate composed of LM3, a human somatostatin receptor (SSTR) antagonist, conjugated to the albumin-binding dye Evans blue (EB) and linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against SSTR-expressing tumor cells. Upon administration, lutetium Lu 177-EB-LM3 targets and binds to SSTRs that are present on the cell membranes of many types of neuroendocrine tumors (NETs). Upon binding, SSTR-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. This agent also binds to serum albumin with its EB moiety which increases this agent’s half-life and decreases its rate of clearance. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTRs.","text":"A radioconjugate composed of LM3, a human somatostatin receptor (SSTR) antagonist, conjugated to the albumin-binding dye Evans blue (EB) and linked to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against SSTR-expressing tumor cells. Upon administration, lutetium Lu 177-EB-LM3 targets and binds to SSTRs that are present on the cell membranes of many types of neuroendocrine tumors (NETs). Upon binding, SSTR-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. This agent also binds to serum albumin with its EB moiety which increases this agent’s half-life and decreases its rate of clearance. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTRs."},"drugInfoSummaryLink":null,"nciConceptId":"C188378","nciConceptName":"Lutetium Lu 177-EB-LM3","termId":810112,"name":"lutetium Lu 177-EB-LM3","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-eb-lm3"},{"aliases":[{"type":"Abbreviation","name":"[177LuDOTA]-TOC"},{"type":"Synonym","name":"177Lu-DOTA-Tyr3-octreotide"},{"type":"Synonym","name":"lutetium Lu 177-DOTA-edotreotide"},{"type":"Synonym","name":"lutetium Lu 177 DOTA-tyr3-octreotide"}],"definition":{"html":"A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).","text":"A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA)."},"drugInfoSummaryLink":null,"nciConceptId":"C88277","nciConceptName":"Lutetium Lu 177-Edotreotide","termId":656307,"name":"lutetium LU 177-edotreotide","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-edotreotide"},{"aliases":[{"type":"Synonym","name":"lutetium 177-NeoB"},{"type":"Synonym","name":"177Lu-NeoB"},{"type":"Synonym","name":"lutetium Lu 177 DOTA-NeoBOMB1"},{"type":"Synonym","name":"[177Lu]-NeoB"}],"definition":{"html":"A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.","text":"A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types."},"drugInfoSummaryLink":null,"nciConceptId":"C158734","nciConceptName":"Lutetium Lu 177-NeoB","termId":797487,"name":"lutetium Lu 177-NeoB","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-neob"},{"aliases":[{"type":"Synonym","name":"177Lu-labeled PSMA I&T"},{"type":"Synonym","name":"Lu-177-PSMA-I&T"},{"type":"Synonym","name":"lutetium Lu 177 PSMA I&T"}],"definition":{"html":"A radioconjugate composed of PSMA-I&T, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon administration of lutetium Lu 177-PSMA-I&T, PSMA-I&T targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.","text":"A radioconjugate composed of PSMA-I&T, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon administration of lutetium Lu 177-PSMA-I&T, PSMA-I&T targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors."},"drugInfoSummaryLink":null,"nciConceptId":"C188987","nciConceptName":"Lutetium Lu 177 Zadavotide Guraxetan","termId":810503,"name":"lutetium Lu 177-PSMA-I&T","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-zadavotide-guraxetan"},{"aliases":[{"type":"Abbreviation","name":"177Lu-DOTA-cG250"},{"type":"Synonym","name":"lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250"},{"type":"Synonym","name":"lutetium-177 labeled cG250"}],"definition":{"html":"A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.","text":"A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate."},"drugInfoSummaryLink":null,"nciConceptId":"C66978","nciConceptName":"Lutetium Lu-177 Girentuximab","termId":531051,"name":"lutetium Lu-177 girentuximab","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-girentuximab"},{"aliases":[{"type":"Synonym","name":"[Lu-177]-PNT2002"},{"type":"Synonym","name":"lutetium Lu-177-PNT2002"},{"type":"Synonym","name":"177Lu-PNT2002"},{"type":"Synonym","name":"177Lu-labeled PNT2002"},{"type":"Synonym","name":"Lu177-PNT2002"},{"type":"Synonym","name":"[Lu-177]-PSMA-I and T"}],"definition":{"html":"A radioconjugate composed of PNT2002, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity. Upon administration of lutetium Lu-177 PNT2002, the PNT2002 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.","text":"A radioconjugate composed of PNT2002, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity. Upon administration of lutetium Lu-177 PNT2002, the PNT2002 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C179300","nciConceptName":"Lutetium Lu 177 Zadavotide Guraxetan","termId":804736,"name":"lutetium Lu-177 PNT2002","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-zadavotide-guraxetan"},{"aliases":[{"type":"Synonym","name":"177Lu-PSMA-R2"},{"type":"Synonym","name":"Lu177-PSMA-R2"},{"type":"Synonym","name":"lutetium-177 PSMA-R2"},{"type":"Synonym","name":"177LuPSMA-R2"}],"definition":{"html":"A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.","text":"A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C150467","nciConceptName":"Lutetium Lu-177 PSMA-R2","termId":793409,"name":"lutetium Lu-177 PSMA-R2","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lutetium-lu-177-psma-r2"},{"aliases":[{"type":"CodeName","name":"PCI-0123"},{"type":"Synonym","name":"lutetium texaphyrin"},{"type":"USBrandName","name":"Antrin"},{"type":"Synonym","name":"lutetium texaphrin"},{"type":"USBrandName","name":"Lutex"},{"type":"USBrandName","name":"Lutrin"},{"type":"INDCode","name":"58536"},{"type":"NSCNumber","name":"695239"},{"type":"CASRegistryName","name":"246252-04-0"}],"definition":{"html":"A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects.","text":"A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects."},"drugInfoSummaryLink":null,"nciConceptId":"C1651","nciConceptName":"Motexafin Lutetium","termId":42402,"name":"motexafin lutetium","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"motexafin-lutetium"}],"links":null}